School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Family Medicine and Palliative Care Program, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Trials. 2023 Sep 25;24(1):606. doi: 10.1186/s13063-023-07614-4.
BACKGROUND: Limited access to specialized palliative care exposes persons with late-stage Alzheimer's disease and related dementias (ADRD) to burdensome treatment and unnecessary hospitalization and their caregivers to avoidable strain and financial burden. Addressing this unmet need, the purpose of this study was to conduct a randomized clinical trial (RCT) of the ADRD-Palliative Care (ADRD-PC) program. METHODS: The study will use a multisite, RCT design and will be set in five geographically diverse US hospitals. Lead investigators and outcome assessors will be masked. The study will use 1:1 randomization of patient-caregiver dyads, and sites will enroll N = 424 dyads of hospitalized patients with late-stage ADRD with their family caregivers. Intervention dyads will receive the ADRD-PC program of (1) dementia-specific palliative care, (2) standardized caregiver education, and (3) transitional care. Control dyads will receive publicly available educational material on dementia caregiving. Outcomes will be measured at 30 days (interim) and 60 days post-discharge. The primary outcome will be 60-day hospital transfers, defined as visits to an emergency department or hospitalization ascertained from health record reviews and caregiver interviews (aim 1). Secondary patient-centered outcomes, ascertained from 30- and 60-day health record reviews and caregiver telephone interviews, will be symptom treatment, symptom control, use of community palliative care or hospice, and new nursing home transitions (aim 2). Secondary caregiver-centered outcomes will be communication about prognosis and goals of care, shared decision-making about hospitalization and other treatments, and caregiver distress (aim 3). Analyses will use intention-to-treat, and pre-specified exploratory analyses will examine the effects of sex as a biologic variable and the GDS stage. DISCUSSION: The study results will determine the efficacy of an intervention that addresses the extraordinary public health impact of late-stage ADRD and suffering due to symptom distress, burdensome treatments, and caregiver strain. While many caregivers prioritize comfort in late-stage ADRD, shared decision-making is rare. Hospitalization creates an opportunity for dementia-specific palliative care, and the study findings will inform care redesign to advance comprehensive dementia-specific palliative care plus transitional care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04948866. Registered on July 2, 2021.
背景:晚期阿尔茨海默病和相关痴呆症(ADRD)患者获得专业姑息治疗的机会有限,这使他们面临治疗负担和不必要的住院治疗,其护理人员也面临着不必要的压力和经济负担。为了满足这一未满足的需求,本研究旨在对 ADRD-姑息治疗(ADRD-PC)计划进行随机临床试验(RCT)。
方法:该研究将采用多地点、RCT 设计,在五家地理位置不同的美国医院进行。主要研究者和结果评估者将被蒙蔽。该研究将对患者-护理人员对进行 1:1 随机分组,各地点将招募 424 对患有晚期 ADRD 的住院患者及其家属护理人员。干预组将接受 ADRD-PC 计划,包括(1)痴呆症特定的姑息治疗,(2)标准化的护理人员教育,以及(3)过渡性护理。对照组将接受关于痴呆症护理的公共教育材料。结果将在 30 天(中期)和 60 天出院后进行测量。主要结局是 60 天内的医院转院,定义为从健康记录审查和护理人员访谈中确定的急诊或住院就诊(目标 1)。从 30 天和 60 天的健康记录审查以及护理人员电话访谈中确定的次要患者为中心的结局将是症状治疗、症状控制、使用社区姑息治疗或临终关怀以及新的疗养院过渡(目标 2)。次要护理人员为中心的结局将是关于预后和护理目标的沟通、关于住院和其他治疗的共同决策以及护理人员的痛苦(目标 3)。分析将采用意向治疗,并且预指定的探索性分析将检查性别作为生物变量和 GDS 阶段的影响。
讨论:研究结果将确定一种干预措施的疗效,该干预措施解决了晚期 ADRD 和因症状痛苦、治疗负担以及护理人员压力而导致的巨大公共卫生影响。虽然许多护理人员将舒适作为晚期 ADRD 的优先事项,但共同决策却很少见。住院为痴呆症特定的姑息治疗创造了机会,研究结果将为重新设计护理提供信息,以推进全面的痴呆症特定姑息治疗加过渡性护理。
试验注册:ClinicalTrials.gov NCT04948866。注册于 2021 年 7 月 2 日。
J Pain Symptom Manage. 2024-11
J Pain Symptom Manage. 2018-10-18
J Pain Symptom Manage. 2024-11
J Am Geriatr Soc. 2019-8-7
J Biomed Inform. 2019-5-9
J Am Med Dir Assoc. 2019-4-28
J Am Geriatr Soc. 2019-8
J Pain Symptom Manage. 2018-11-17
J Pain Symptom Manage. 2018-10-18
Gerontologist. 2018-1-18
J Pain Symptom Manage. 2017-12-27
J Pain Symptom Manage. 2017-8-8
J Palliat Med. 2017-8-3